Health Outcomes Division, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
TxCORE-Texas Center for Health Outcomes Research and Education, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
Curr Med Res Opin. 2021 Aug;37(8):1315-1322. doi: 10.1080/03007995.2021.1923469. Epub 2021 Jun 21.
To estimate the prevalence of primary immune thrombocytopenia (ITP) and describe ITP-associated healthcare resource utilization (HRU) among Texas Medicaid beneficiaries.
A retrospective analysis using 2012-2015 Texas Medicaid claims data was conducted to estimate the annual prevalence of ITP. HRU was summarized for the 12-month period following initial ITP diagnosis. Logistic regression and generalized linear model were used to investigate predictors for all-cause and ITP-related HRU.
The average annual prevalence of ITP was 17.0 per 100,000 persons; higher among females vs males (17.4 vs 13.6 per 100,000) and highest among adults aged ≥ 65 years (36.7 per 100,000). Among 325 patients included in the HRU analyses, 49.2% received ITP therapies. More than half of patients had at least one all-cause emergency department (ED) visit (70.5%) and/or hospitalization (56.0%). One-third (32.6%) experienced at least one ITP-related ED visit and 40.3% had at least one ITP-related hospitalization. Compared to adults aged 18-49 with ITP, children aged 0-4 (odds ratio [OR] = 3.65, = .0008) and aged 5-17 (OR = 2.68, = .0074) were more likely to have an ITP-related hospitalization; children aged 0-4 (OR = 4.36, = .0005) and children aged 5-17 (OR = 4.09, = .0005) were more likely to have an ITP-related ED visit during the follow-up period.
There are 17 patients diagnosed with ITP for every 100,000 Texas Medicaid enrollees annually, with higher prevalence in females and the elderly. Children are more likely to experience hospitalizations and ED visits associated with ITP. ITP patients in Texas Medicaid utilize more healthcare resources compared to the general Medicaid population.
评估德克萨斯州医疗补助计划（Medicaid）受益人群中原发性免疫性血小板减少症（ITP）的患病率，并描述与 ITP 相关的医疗资源利用（HRU）情况。
利用 2012-2015 年德克萨斯州 Medicaid 理赔数据进行回顾性分析，以估算 ITP 的年患病率。总结初次诊断 ITP 后 12 个月的 HRU。采用逻辑回归和广义线性模型，分析全因和与 ITP 相关的 HRU 的预测因素。
ITP 的平均年患病率为 17.0/10 万；女性高于男性（17.4/ vs 13.6/），年龄≥65 岁的成年人患病率最高（36.7/）。在纳入 HRU 分析的 325 例患者中，49.2%接受 ITP 治疗。超过一半的患者至少有一次全因急诊就诊（70.5%）和/或住院治疗（56.0%）。三分之一（32.6%）至少有一次与 ITP 相关的急诊就诊，40.3%至少有一次与 ITP 相关的住院治疗。与患有 ITP 的 18-49 岁成年人相比，0-4 岁（比值比[OR] = 3.65， =.0008）和 5-17 岁（OR = 2.68， =.0074）的儿童更有可能因 ITP 而住院治疗；0-4 岁（OR = 4.36， =.0005）和 5-17 岁（OR = 4.09， =.0005）的儿童在随访期间更有可能因 ITP 而就诊急诊。
德克萨斯州 Medicaid 计划每年每 10 万参保人群中就有 17 例患者被诊断为 ITP，女性和老年人的患病率更高。儿童更有可能因 ITP 而住院和就诊急诊。与一般 Medicaid 人群相比，德克萨斯州 Medicaid 的 ITP 患者使用了更多的医疗资源。
